The latest data from an early Phase I study includes an analysis from 20 additional people detailing how the vaccine performed in older adults. Health officials have been concerned about whether vaccine candidates would work in older people, whose immune systems typically do not respond as strongly to vaccines. Pfizer Inc told Reuters last week that 19% of the 11,000 subjects already enrolled in its vaccine trial are Black or Latino. Moderna is also working to make the vaccine stable at higher temperatures, Miller said. Moderna, which has never brought a vaccine to market, has received nearly $1 billion from the US government under its Operation Warp Speed program.

Source: bd News24 August 26, 2020 18:22 UTC